PRODUCT INFORMATION



Gestodene-d₄ Item No. 33819

CAS Registry No.: 1542211-40-4

Formal Name: 13-ethyl-17α-hydroxy-18,19-dinorpregna-4,15-

dien-20-yn-3-one-2,2,4,6,6,10-d₄

MF: $C_{21}H_{20}D_6O_2$ FW: 316.5


Chemical Purity: ≥98% (Gestodene)

Deuterium

Incorporation: \geq 99% deuterated forms (d₁-d₆); \leq 1% d₀

Supplied as: A solid Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

Gestodene-d₆ is intended for use as an internal standard for the quantification of gestodene (Item No. 18217) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Gestodene-d, is supplied as a solid. A stock solution may be made by dissolving the gestodene-d, in the solvent of choice, which should be purged with an inert gas. Gestodene- d_{λ} is soluble in methanol.

Description

Gestodene is a progestin.¹ It selectively binds to the progesterone receptor over the estrogen receptor.² Gestodene induces transcriptional activity mediated by the progesterone receptor, and, weakly, the androgen receptor in reporter assays.3 It increases the growth of MCF-7 cells when used at concentrations ranging from 0.1 to 1 µM.4 In contrast, gestodene (0.1 mg/kg) reduces tumor growth in an estrogen-dependent model of rat mammary tumors induced by DMBA (Item No. 30383). Formulations containing gestodene, in combination with ethynyl estradiol have been used as oral contraceptives.

References

- 1. Stanczyk, F.Z. All progestins are not created equal. Steroids 68(10-13), 879-890 (2003).
- 2. Pollow, K., Juchem, M., Grill, H.J., et al. Lack of binding of gestodene to estrogen receptor in human breast cancer tissue. Eur. J. Cancer 26(5), 608-610 (1990).
- Fuhrmann, U., Slater, E.P., and Fritzemeier, K.H. Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays. Contraception 51(1), 45-52 (1995).
- Kloosterboer, H.J., Schoonen, W.G., Deckers, G.H.J., et al. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. J. Steroid Biochem. Mol. Biol. 49(4-6), 311-318 (1994).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 11/17/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM